B3(Fv)-PE38KDEL recombinant immunotoxin

composed of the heavy chain V(H) region of the carcinoma specific Mab B3 connected by a flexible linker peptide to the corresponding light chain V(L) which is in turn fused to a truncated form of Pseudomonas exotoxin

Also Known As:

Networked: 21 relevant articles (4 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kreitman, Robert J: 9 articles (01/2016 - 02/2002)
2.	Pastan, Ira: 7 articles (01/2018 - 02/2002)
3.	Kreitman, R J: 5 articles (12/2001 - 02/2000)
4.	Pastan, I: 3 articles (12/2000 - 04/2000)
5.	Stetler-Stevenson, Maryalice: 2 articles (01/2016 - 06/2011)
6.	Stetler-Stevenson, M: 2 articles (04/2000 - 02/2000)
7.	Jang, Youjin: 1 article (01/2018)
8.	Kaplan, Gilad: 1 article (01/2018)
9.	Lee, Fred: 1 article (01/2018)
10.	Leshem, Yasmin: 1 article (01/2018)

Related Diseases

1.	Leukemia 12/15/2000 - "Recent clinical trials showed that LMB-2 is a promising agent for the treatment of patients with Tac-positive leukemia or lymphoma. " 10/01/1995 - "Anti-Tac(Fv)-PE38, a single-chain recombinant immunotoxin which targets cells bearing the IL2Ra, is furthest along in preclinical development and is being prepared for clinical testing in patients with IL2Ra-positive leukemia, lymphoma and Hodgkin's disease." 01/15/2016 - "LMB-2, administered with fludarabine and cyclophosphamide to prevent antidrug antibodies and rapid intercycle progression, is highly effective in achieving CR in leukemia ATL. " 12/01/1999 - "Anti-Tac(Fv)-PE38, also called LMB-2, is a very active recombinant immunotoxin that has produced eight responses, including a durable clinical complete remission in a recently completed phase I trial of leukemias and lymphomas. "
2.	Lymphoma (Lymphomas) 12/15/2000 - "Recent clinical trials showed that LMB-2 is a promising agent for the treatment of patients with Tac-positive leukemia or lymphoma. " 10/01/1995 - "Anti-Tac(Fv)-PE38, a single-chain recombinant immunotoxin which targets cells bearing the IL2Ra, is furthest along in preclinical development and is being prepared for clinical testing in patients with IL2Ra-positive leukemia, lymphoma and Hodgkin's disease." 12/01/1999 - "Anti-Tac(Fv)-PE38, also called LMB-2, is a very active recombinant immunotoxin that has produced eight responses, including a durable clinical complete remission in a recently completed phase I trial of leukemias and lymphomas. "
3.	Neoplasms (Cancer) 01/01/2012 - "CD25(+) human xenografts growing rapidly in nude mice had intratumoral sCD25 at levels that were between 21- and 2,200 (median 118)-fold higher than in serum, indicating that interstitial sCD25 interacts with LMB-2 in tumors. " 03/01/1998 - "Sections of tumor examined by autoradiography indicated that anti-Tac(Fv)-PE38 was distributed throughout the entire tumor, with some portions having higher uptake than others. " 03/01/1998 - "125I-labeled anti-Tac(Fv)-PE38 was given i.v. to immunodeficient mice each bearing two A431 tumors, one that expresses IL2R alpha (ATAC-4) and one that does not (A431, parental). " 01/01/2012 - "Synergism, therefore, appears to be related to improved distribution of LMB-2 to CD25(+) tumors, and is preceded by decreased sCD25 within the tumor because of chemotherapy. " 01/01/2012 - "Tumor xenografts expressing human CD25 were grown in mice, which were then treated with LMB-2 and chemotherapy either alone or in combination, and sCD25 level and antitumor activity were measured. "
4.	Hairy Cell Leukemia 02/01/2000 - "Hairy cell leukemia (HCL) is a B-cell malignancy in which the cells are usually CD25+ and their ex vivo sensitivity to LMB-2 was unknown. " 02/01/2000 - "Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2)." 11/15/1999 - "We report major responses in 4 of 4 patients with hairy cell leukemia (HCL) who have recently been treated on a phase I trial with the recombinant immunotoxin LMB-2. " 02/15/2002 - "A recombinant anti-CD25 immunotoxin, LMB-2, has shown clinical efficacy in hairy cell leukemia and T-cell neoplasms. " 01/01/2012 - "Although anti-CD25 recombinant immunotoxin LMB-2 is effective against CD25(+) hairy cell leukemia, activity against more aggressive diseases such as adult T-cell leukemia (ATL) is limited by rapid disease progression between treatment cycles. "
5.	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 01/15/2016 - "Complete Remissions of Adult T-cell Leukemia with Anti-CD25 Recombinant Immunotoxin LMB-2 and Chemotherapy to Block Immunogenicity." 01/01/2012 - "Although anti-CD25 recombinant immunotoxin LMB-2 is effective against CD25(+) hairy cell leukemia, activity against more aggressive diseases such as adult T-cell leukemia (ATL) is limited by rapid disease progression between treatment cycles. " 01/01/2009 - "Major responses were observed with LMB-2 in adult T-cell leukemia, chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma, Hodgkin's disease, and hairy cell leukemia (HCL). " 04/01/2002 - "Therapy with an immunotoxin, anti-Tac(Fv)-PE38, which is a conjugate of the variable domains of an anti-Tac monoclonal antibody and Pseudomonas exotoxin, was reported to be useful for adult T cell leukemia (ATL) patients but a considerable amount of the immunotoxin is needed for the therapy and some side effects were also observed. "

Related Drugs and Biologics

1.	Immunotoxins (Immunotoxin)
2.	B3(Fv)-PE38KDEL recombinant immunotoxin
3.	Antibodies
4.	Cyclophosphamide (Cytoxan)
5.	fludarabine
6.	Interleukin-2 Receptor alpha Subunit
7.	Peptides (Polypeptides)
8.	Bacterial Toxins
9.	Exotoxins
10.	Immunoglobulin Variable Region

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Intravenous Administration
4.	Salvage Therapy